These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25489551)

  • 1. Cushing, acromegaly, GH deficiency and tendons.
    Galdiero M; Auriemma RS; Pivonello R; Colao A
    Muscles Ligaments Tendons J; 2014 Jul; 4(3):329-32. PubMed ID: 25489551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone deficiency in treated acromegaly and active Cushing's syndrome.
    Formenti AM; Maffezzoni F; Doga M; Mazziotti G; Giustina A
    Best Pract Res Clin Endocrinol Metab; 2017 Feb; 31(1):79-90. PubMed ID: 28477735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease.
    Feldt-Rasmussen U; Abs R; Bengtsson BA; Bennmarker H; Bramnert M; Hernberg-Ståhl E; Monson JP; Westberg B; Wilton P; Wüster C;
    Eur J Endocrinol; 2002 Jan; 146(1):67-74. PubMed ID: 11751070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone (GH) deficiency and GH replacement therapy in patients previously treated for Cushing's disease.
    Boguszewski CL
    Pituitary; 2022 Oct; 25(5):760-763. PubMed ID: 35552989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone status following treatment for Cushing's syndrome.
    Hughes NR; Lissett CA; Shalet SM
    Clin Endocrinol (Oxf); 1999 Jul; 51(1):61-6. PubMed ID: 10468966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ghrelin is no longer able to stimulate growth hormone secretion in patients with Cushing's syndrome but instead induces exaggerated corticotropin and cortisol responses.
    Leal-Cerro A; Torres E; Soto A; Dios E; Deghenghi R; Arvat E; Ghigo E; Dieguez C; Casanueva FF
    Neuroendocrinology; 2002 Dec; 76(6):390-6. PubMed ID: 12566947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess.
    Ciresi A; Giordano C
    Growth Horm IGF Res; 2017 Apr; 33():35-42. PubMed ID: 28372721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of 11β-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients.
    Morgan SA; Berryman DE; List EO; Lavery GG; Stewart PM; Kopchick JJ
    Growth Horm IGF Res; 2022 Feb; 62():101440. PubMed ID: 34814007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
    Stewart PM; Toogood AA; Tomlinson JW
    Horm Res; 2001; 56 Suppl 1():1-6. PubMed ID: 11786677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
    Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
    Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
    Leal-Cerro A; Pumar A; Villamil F; Astorga R; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome.
    Tzanela M; Karavitaki N; Stylianidou C; Tsagarakis S; Thalassinos NC
    Clin Endocrinol (Oxf); 2004 Mar; 60(3):309-14. PubMed ID: 15008995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acromegaly and Cushing's syndrome due to ectopic production of GHRH and ACTH by a thymic carcinoid tumour: in vitro responses to GHRH and GHRP-6.
    Jansson JO; Svensson J; Bengtsson BA; Frohman LA; Ahlman H; Wängberg B; Nilsson O; Nilsson M
    Clin Endocrinol (Oxf); 1998 Feb; 48(2):243-50. PubMed ID: 9579239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GH-IGF-I axis and the cardiovascular system: clinical implications.
    Colao A
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cardiovascular system in growth hormone excess and growth hormone deficiency.
    Lombardi G; Di Somma C; Grasso LF; Savanelli MC; Colao A; Pivonello R
    J Endocrinol Invest; 2012 Dec; 35(11):1021-9. PubMed ID: 23143695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid-labile subunit in growth hormone excess and deficiency in adults: evaluation of its diagnostic value in comparison with insulin-like growth factor (IGF)-I and IGF-binding protein-3.
    Fukuda I; Hizuka N; Itoh E; Yasumoto K; Ishikawa Y; Murakami Y; Sata A; Takano K
    Endocr J; 2002 Jun; 49(3):379-86. PubMed ID: 12201224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.